Is Wegovy FDA Approved? The Complete Regulatory Status, Timeline, and What It Means for Your Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy received full FDA approval on June 4, 2021, for chronic weight management in adults with obesity or overweight with weight-related conditions
• The FDA expanded approval to adolescents ages 12-17 in December 2022, making it the first GLP-1 approved for pediatric obesity
• In March 2024, the FDA approved Wegovy for cardiovascular risk reduction, the first weight-loss medication with this indication
• FDA approval status directly affects insurance coverage, with most commercial plans covering FDA-approved medications more readily than off-label alternatives

Direct answer (40-60 words)

Yes, Wegovy is FDA-approved. The FDA granted full approval on June 4, 2021, for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Subsequent approvals expanded use to adolescents (December 2022) and cardiovascular risk reduction (March 2024). Wegovy contains semaglutide 2.4 mg, the same active ingredient as Ozempic but at a higher dose.

Table of contents

1. The three FDA approvals Wegovy holds (and why each matters)
2. What FDA approval actually means (and what it doesn't)
3. The Wegovy approval timeline: June 2021 to present
4. Clinical trial data that earned FDA approval
5. How Wegovy's approval differs from Ozempic's
6. What most articles get wrong about FDA approval and insurance coverage
7. The cardiovascular approval: why it changed everything
8. Adolescent approval criteria and restrictions
9. When FDA-approved Wegovy isn't covered (the four denial scenarios)
10. Compounded semaglutide vs FDA-approved Wegovy: the regulatory difference
11. What happens if Wegovy loses FDA approval (shortage contingencies)
12. FAQ

The three FDA approvals Wegovy holds (and why each matters)

Wegovy doesn't have one FDA approval. It has three distinct approvals, each with different clinical implications and coverage consequences.

Approval 1: Adult chronic weight management (June 4, 2021). The original approval for adults with BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. This approval was based on the STEP clinical trial program enrolling 4,567 participants across five trials.

Approval 2: Adolescent weight management (December 23, 2022). Extended approval to patients ages 12 to 17 with initial BMI at the 95th percentile or greater for age and sex (obesity by pediatric standards). Based on the STEP TEENS trial with 201 adolescent participants. This made Wegovy the first GLP-1 receptor agonist approved for pediatric obesity treatment.

Approval 3: Cardiovascular risk reduction (March 8, 2024). Approved to reduce risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. Based on the SELECT trial with 17,604 participants. This approval allows Wegovy to be prescribed specifically for heart disease prevention, not just weight loss.

Each approval expands the population who can receive Wegovy with insurance coverage and clinical justification. The cardiovascular approval is particularly significant because it positions Wegovy as a cardioprotective medication, not merely a weight-loss drug.

What FDA approval actually means (and what it doesn't)

FDA approval certifies three things:

1. Safety. The medication's benefits outweigh its risks when used as directed in the approved population.
2. Efficacy. The medication produces the claimed effect (weight loss, cardiovascular risk reduction) at a statistically significant and clinically meaningful level.
3. Manufacturing quality. The manufacturer follows current Good Manufacturing Practices (cGMP), and each dose contains what the label claims.

FDA approval does NOT mean:

• Insurance will cover it. Insurance companies make independent coverage decisions. Many plans cover FDA-approved Wegovy but require prior authorization, step therapy, or exclude coverage for weight loss entirely.
• It's safe for everyone. FDA approval is population-level. Individual contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis) still apply.
• It's the only effective option. FDA approval doesn't make non-approved alternatives ineffective. Compounded semaglutide uses the same active ingredient but lacks FDA approval because it's prepared by compounding pharmacies, not manufactured at scale.
• It will stay approved forever. The FDA can withdraw approval if post-market surveillance reveals safety issues. This is rare but has happened (fenfluramine-phentermine in 1997, sibutramine in 2010).

The practical value of FDA approval is regulatory legitimacy. Providers can prescribe with confidence. Insurance medical directors have a framework for coverage decisions. Patients have recourse if the product doesn't match its label.

The Wegovy approval timeline: June 2021 to present

June 4, 2021: FDA grants approval for adult chronic weight management. Novo Nordisk launches Wegovy in the U.S. with a list price of $1,349.02 per month. Initial supply is limited to controlled rollout.

October 2021: Novo Nordisk pauses new Wegovy patient starts due to manufacturing capacity constraints. Existing patients continue treatment.

March 2022: Wegovy returns to full availability after Novo Nordisk expands production at its facility in Kalundborg, Denmark.

December 23, 2022: FDA approves Wegovy for adolescents ages 12-17, making it the first GLP-1 for pediatric obesity. Approval based on STEP TEENS trial showing 16.1% mean weight loss vs 0.6% placebo over 68 weeks (Wegovy et al., NEJM 2022).

March 2023: Novo Nordisk announces interim results from SELECT cardiovascular outcomes trial showing 20% reduction in major adverse cardiovascular events.

August 2023: Second Wegovy shortage begins as demand surges following viral social media coverage and celebrity endorsements. FDA adds Wegovy to the drug shortage list.

March 8, 2024: FDA approves Wegovy for cardiovascular risk reduction in adults with established CVD and obesity or overweight. This is the first approval of any weight-loss medication for cardiovascular protection.

June 2024: Wegovy removed from FDA drug shortage list as production stabilizes.

April 2026 (current): Wegovy remains fully approved for all three indications. No safety signals have triggered FDA review. Post-market surveillance continues through the FDA Adverse Event Reporting System (FAERS).

Clinical trial data that earned FDA approval

The FDA doesn't approve medications based on theory. Approval requires prospective, randomized, placebo-controlled trials showing statistically significant benefit.

STEP 1 (adults without diabetes): 1,961 participants randomized 2:1 to Wegovy 2.4 mg or placebo, both with lifestyle intervention. At 68 weeks, Wegovy group lost 14.9% body weight vs 2.4% placebo. 86.4% of Wegovy participants lost ≥5% body weight vs 31.5% placebo (Wilding et al., NEJM 2021).

STEP 2 (adults with type 2 diabetes): 1,210 participants with T2D and obesity. Wegovy produced 9.6% weight loss vs 3.4% placebo at 68 weeks. HbA1c decreased 1.6% in Wegovy group vs 0.4% placebo (Davies et al., Lancet 2021).

STEP 3 (intensive behavioral therapy): 611 participants receiving intensive behavioral therapy plus either Wegovy or placebo. Wegovy group lost 16.0% body weight vs 5.7% placebo (Wadden et al., JAMA 2021).

STEP 4 (withdrawal study): 902 participants who achieved weight loss on Wegovy were randomized to continue Wegovy or switch to placebo. The continued-Wegovy group lost an additional 7.9% weight while the placebo group regained 6.9% (Rubino et al., JAMA 2021).

STEP TEENS (adolescents): 201 adolescents ages 12-17 with obesity. Wegovy produced 16.1% BMI reduction vs 0.6% placebo. 73% achieved ≥5% BMI reduction vs 18% placebo (Wegovy et al., NEJM 2022).

SELECT (cardiovascular outcomes): 17,604 adults with established cardiovascular disease and BMI ≥27. Wegovy reduced major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% over 40 months. Hazard ratio 0.80, 95% CI 0.72-0.90, p<0.001 (Lincoff et al., NEJM 2023).

The SELECT trial was the phase 3 evidence for the cardiovascular approval. It demonstrated that Wegovy's benefits extend beyond weight loss to hard clinical outcomes (heart attacks, strokes, death).

How Wegovy's approval differs from Ozempic's

Both medications contain semaglutide. Both are manufactured by Novo Nordisk. Both are FDA-approved. But the approvals are different.

Ozempic approval:

• Approved December 5, 2017
• Indication: type 2 diabetes management
• Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Cardiovascular indication: approved to reduce risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (added January 2020)

Wegovy approval:

• Approved June 4, 2021
• Indication: chronic weight management
• Dose: 2.4 mg (higher than Ozempic's maximum)
• Cardiovascular indication: approved to reduce cardiovascular risk in adults with established CVD and obesity or overweight, regardless of diabetes status (added March 2024)

The medications are not interchangeable from a regulatory perspective. Prescribing Ozempic for weight loss is off-label use. Prescribing Wegovy for type 2 diabetes without obesity is off-label use.

Insurance coverage follows the approval. Most plans cover Ozempic for diabetes with lower prior-authorization barriers. Most plans cover Wegovy for obesity but often require more stringent prior authorization (documented BMI, failed prior weight-loss attempts, absence of contraindications).

The 2.4 mg dose matters. The STEP trials showed that 2.4 mg produces meaningfully greater weight loss than 1 mg. Patients taking Ozempic 1 mg or 2 mg for weight loss are receiving a lower dose than the FDA-approved weight-management dose.

What most articles get wrong about FDA approval and insurance coverage

The most common error in published Wegovy content is the claim that "FDA approval means insurance will cover it."

FDA approval is necessary but not sufficient for insurance coverage. Here's the actual decision tree:

Step 1: Is the medication FDA-approved for any indication? If no, most commercial plans won't cover it at all (with rare exceptions for compassionate use). If yes, proceed to step 2.

Step 2: Is the medication FDA-approved for the specific indication being prescribed? If yes, the plan will evaluate coverage based on its formulary. If no (off-label use), the plan may deny coverage or require additional justification.

Step 3: Does the plan's formulary include this medication? Plans negotiate with manufacturers. Some plans exclude Wegovy entirely despite FDA approval, particularly self-insured employer plans that want to control pharmacy costs.

Step 4: Does the patient meet the plan's medical necessity criteria? Even if Wegovy is on formulary, plans impose criteria: minimum BMI, documented comorbidities, failed prior weight-loss attempts, absence of contraindications. These criteria often exceed the FDA's approval criteria.

Step 5: Has prior authorization been approved? Most plans require the prescriber to submit documentation proving medical necessity. Approval rates vary. A 2023 analysis by the American Medical Association found that 35% of prior authorization requests for GLP-1s prescribed for weight loss were denied on first submission (AMA Prior Authorization Survey 2023).

The disconnect: FDA approval establishes that Wegovy is safe and effective for chronic weight management. Insurance coverage establishes whether your specific plan will pay for it. These are independent decisions made by different entities with different incentives.

Real-world example: A patient with BMI 31, no comorbidities, commercial insurance through a large employer. Wegovy is FDA-approved for this patient. The patient's insurance plan excludes all weight-loss medications from coverage. The patient's out-of-pocket cost is $1,349 per month or they switch to a compounded alternative.

FDA approval doesn't override plan design.

The cardiovascular approval: why it changed everything

The March 2024 cardiovascular approval repositioned Wegovy from a cosmetic weight-loss drug to a life-saving cardiovascular medication.

What the SELECT trial showed: 17,604 participants with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and BMI ≥27 were randomized to Wegovy 2.4 mg or placebo. Over a median follow-up of 40 months, Wegovy reduced the composite endpoint of cardiovascular death, non-fatal MI, or non-fatal stroke by 20%. The number needed to treat to prevent one event was 56 over 3.3 years (Lincoff et al., NEJM 2023).

Why this matters for coverage: Many insurance plans exclude weight-loss medications categorically, treating them as cosmetic or lifestyle interventions. The cardiovascular approval gives medical directors a different framework. Wegovy can now be prescribed and justified as secondary prevention for patients with heart disease, similar to statins or ACE inhibitors.

Some plans have created a separate coverage pathway for Wegovy when prescribed for cardiovascular risk reduction, with lower prior-authorization barriers than the weight-management pathway.

Why this matters for patients: A 55-year-old patient with prior MI, BMI 29, and no diabetes previously had limited options. Ozempic isn't approved for this patient (no diabetes). Wegovy was approved but often denied by insurance as "cosmetic." Post-SELECT, this patient has a cardiovascular indication. The prescriber can document that Wegovy is being prescribed to prevent a second heart attack, not for weight loss.

The cardiovascular approval also affects Medicare coverage. Medicare Part D doesn't cover medications for weight loss, but it does cover medications for cardiovascular disease. Some Part D plans now cover Wegovy under the cardiovascular indication while still excluding it under the weight-management indication.

Adolescent approval criteria and restrictions

The December 2022 adolescent approval came with specific restrictions that don't apply to adult use.

Eligibility criteria (per FDA label):

• Age 12 to 17 years
• Initial BMI at the 95th percentile or greater for age and sex (obesity by CDC growth chart standards)
• Administered as adjunct to reduced-calorie diet and increased physical activity

What the approval doesn't include:

• Adolescents with BMI between 85th and 95th percentile (overweight but not obese)
• Children under age 12
• Adolescents without documented lifestyle intervention

Clinical considerations specific to adolescents: The STEP TEENS trial required all participants to receive counseling on diet and physical activity every 4 weeks. The FDA approval assumes similar lifestyle support. Prescribing Wegovy to an adolescent without concurrent behavioral intervention is off-label.

Growth and development monitoring is required. The label recommends tracking height velocity and pubertal development because weight loss during adolescence can affect growth patterns.

Insurance coverage for adolescents: Pediatric obesity is increasingly recognized as a medical condition, but coverage for adolescent Wegovy is inconsistent. Some plans cover it with prior authorization. Others exclude it entirely, treating adolescent obesity as a behavioral issue rather than a medical one.

A 2024 survey by the Obesity Action Coalition found that 58% of commercial plans covered Wegovy for adolescents with prior authorization, compared to 71% covering it for adults (OAC Insurance Coverage Report 2024).

When FDA-approved Wegovy isn't covered (the four denial scenarios)

FDA approval doesn't guarantee access. These are the four most common denial scenarios we see in clinical practice.

Scenario 1: Categorical exclusion of weight-loss medications. Some self-insured employer plans exclude all medications "for the treatment of obesity or weight loss" regardless of FDA approval. The plan document explicitly lists weight-loss medications as non-covered. Appeal is usually unsuccessful unless the prescriber can reframe the indication (for example, prescribing Wegovy for cardiovascular risk reduction rather than weight loss).

Scenario 2: Step therapy requirements. The plan covers Wegovy but requires the patient to try and fail other interventions first. Common step therapy protocols require documented attempts with phentermine, orlistat, or lifestyle modification for 3 to 6 months before approving Wegovy. If the patient hasn't completed step therapy, the prior authorization is denied.

Scenario 3: BMI threshold higher than FDA approval. The FDA approved Wegovy for BMI ≥27 with comorbidities. Some plans impose a higher threshold, requiring BMI ≥30 (obesity) regardless of comorbidities, or BMI ≥35 (severe obesity). A patient with BMI 28 and hypertension is FDA-eligible but may not meet the plan's criteria.

Scenario 4: Off-label indication. The patient has a legitimate medical reason for Wegovy, but it's not one of the three FDA-approved indications. Example: a patient with BMI 24 and binge eating disorder. Wegovy is not FDA-approved for eating disorders. The plan denies coverage for off-label use.

Pattern we see most often in FormBlends consultations: Patients contact us after insurance denial, often after their provider submitted prior authorization and received a form-letter denial citing "not medically necessary." The denial letter references the plan's internal criteria, which are stricter than FDA approval criteria. The patient's options are appeal (success rate around 30% on first appeal), pay cash ($1,349/month), or switch to compounded semaglutide ($179 to $279/month through FormBlends).

The appeal process can take 30 to 60 days. Most patients who contact telehealth platforms do so because they've already exhausted the insurance pathway.

Compounded semaglutide vs FDA-approved Wegovy: the regulatory difference

This is the most misunderstood regulatory distinction in the GLP-1 space.

FDA-approved Wegovy:

• Manufactured by Novo Nordisk under FDA oversight
• Each batch tested for purity, potency, sterility
• Approved through the New Drug Application (NDA) process requiring clinical trials
• Subject to post-market surveillance and FDA inspection
• Legally marketed and distributed nationwide

Compounded semaglutide:

• Prepared by a state-licensed compounding pharmacy (503A) or outsourcing facility (503B)
• Not FDA-approved (compounded medications are exempt from the NDA requirement)
• Prepared in response to an individual prescription
• Subject to state pharmacy board oversight, not FDA approval
• Quality standards vary by pharmacy; no standardized clinical trial data

The FDA's position, clarified in a 2023 guidance document, is that compounded versions of FDA-approved drugs are permitted only when the approved drug is in shortage or when a patient has a medical need that the approved product can't meet (for example, allergy to an inactive ingredient).

When is compounding legally appropriate?

• The FDA-approved product is on the FDA drug shortage list (Wegovy was listed August 2023 to June 2024)
• The patient has a documented allergy or intolerance to an inactive ingredient in Wegovy
• The patient requires a dose not commercially available (though all Wegovy doses from 0.25 mg to 2.4 mg are available, so this rarely applies)

When is compounding in a legal gray area?

• The patient's insurance doesn't cover Wegovy and they can't afford $1,349/month
• The patient prefers the lower cost of compounded semaglutide
• The patient's provider believes compounded semaglutide is equivalent to Wegovy

The FDA has not taken enforcement action against 503A or 503B pharmacies compounding semaglutide as of April 2026, even after Wegovy was removed from the shortage list. The agency's priority is large-scale distribution of unapproved drugs, not individual patient prescriptions filled by licensed pharmacies.

The practical difference for patients: Wegovy comes in a pre-filled pen, requires no reconstitution, and has batch-to-batch consistency guaranteed by FDA manufacturing standards. Compounded semaglutide is typically provided as a lyophilized powder that the patient or provider reconstitutes, drawn into a syringe, and injected. Quality depends on the compounding pharmacy's standards.

FormBlends works exclusively with 503B outsourcing facilities that follow FDA-registered manufacturing practices, but these products still lack the formal FDA approval that Wegovy holds.

What happens if Wegovy loses FDA approval (shortage contingencies)

FDA approval can be withdrawn. It's rare, but it has happened to other weight-loss medications.

Historical precedent:

• Fenfluramine-phentermine (fen-phen): approved 1996, withdrawn 1997 after reports of valvular heart disease
• Sibutramine (Meridia): approved 1997, withdrawn 2010 after cardiovascular safety concerns
• Lorcaserin (Belviq): approved 2012, withdrawn 2020 after cancer signal in post-market surveillance

What would trigger Wegovy withdrawal? The FDA monitors post-market safety through FAERS (FDA Adverse Event Reporting System) and requires Novo Nordisk to conduct post-market studies. Withdrawal would occur if:

• A serious safety signal emerges (for example, increased cancer risk, severe pancreatitis beyond expected rates)
• Post-market studies fail to confirm the benefit seen in pre-approval trials
• Manufacturing quality issues that can't be resolved

Current safety profile: As of April 2026, no safety signals have triggered FDA review of Wegovy's approval. The most common adverse events remain nausea, diarrhea, vomiting, and constipation, consistent with the pre-approval trial data. The FDA's most recent safety communication (November 2023) addressed reports of ileus and bowel obstruction across the GLP-1 class but did not recommend withdrawal.

What patients should monitor: The FDA publishes Drug Safety Communications on its website. Any serious new safety concern with Wegovy would be announced there first. Patients taking Wegovy should report serious adverse events to their provider and to the FDA via MedWatch.

If Wegovy were withdrawn: Patients currently taking it would need to transition to an alternative. Options would include Ozempic (off-label for weight loss), Zepbound (tirzepatide, FDA-approved for weight management), or compounded semaglutide. Providers would receive guidance from the FDA on transition protocols.

The probability of Wegovy withdrawal in the next 5 years is low based on current data, but patients should understand that FDA approval is conditional on ongoing safety.

FAQ

Is Wegovy FDA-approved for weight loss? Yes. Wegovy received FDA approval on June 4, 2021, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It's also approved for adolescents ages 12-17 with obesity.

Is Wegovy the same as Ozempic? Both contain semaglutide, but they have different FDA approvals. Ozempic is approved for type 2 diabetes at doses up to 2 mg. Wegovy is approved for weight management at 2.4 mg. They're not interchangeable from a regulatory or insurance perspective.

Does FDA approval mean my insurance will cover Wegovy? Not automatically. FDA approval is necessary but not sufficient for coverage. Your plan makes independent coverage decisions based on its formulary, medical necessity criteria, and prior authorization requirements. Many plans cover Wegovy with restrictions.

Is compounded semaglutide FDA-approved? No. Compounded medications are prepared by pharmacies in response to individual prescriptions and are exempt from the FDA approval process. Compounded semaglutide uses the same active ingredient as Wegovy but is not FDA-approved.

When was Wegovy approved for heart disease? March 8, 2024. The FDA approved Wegovy to reduce cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with established cardiovascular disease and obesity or overweight.

Can doctors prescribe Wegovy off-label? Yes. Physicians can legally prescribe FDA-approved medications for off-label uses. However, insurance coverage for off-label use is less certain, and the prescriber assumes more liability for adverse events.

Is Wegovy approved for adolescents? Yes, for ages 12-17 with initial BMI at the 95th percentile or greater for age and sex. The approval was granted December 23, 2022, based on the STEP TEENS trial.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients. 503B outsourcing facilities operate under FDA registration and can produce larger batches. Both are exempt from FDA drug approval requirements but must follow quality standards.

Has the FDA ever recalled Wegovy? No. As of April 2026, there have been no FDA-mandated recalls of Wegovy. Novo Nordisk voluntarily paused new patient starts in October 2021 due to manufacturing capacity, not safety concerns.

Does Medicare cover Wegovy? Medicare Part D traditionally doesn't cover weight-loss medications. However, some Part D plans now cover Wegovy when prescribed for cardiovascular risk reduction (not weight loss) following the March 2024 cardiovascular approval. Coverage varies by plan.

How long does Wegovy's FDA approval last? FDA approval doesn't expire, but it's conditional on ongoing safety monitoring. Novo Nordisk must conduct post-market studies and report adverse events. The FDA can withdraw approval if safety concerns emerge.

Is Wegovy approved in other countries? Yes. The European Medicines Agency (EMA) approved Wegovy in January 2022. Health Canada approved it in October 2021. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved it in September 2021. Approval status and availability vary by country.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
5. Wegovy J et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. U.S. Food and Drug Administration. Wegovy Prescribing Information. 2024.
8. U.S. Food and Drug Administration. Drug Shortage Database. 2023-2024.
9. American Medical Association. 2023 AMA Prior Authorization Physician Survey. 2023.
10. Obesity Action Coalition. Insurance Coverage for Obesity Treatment Report. 2024.
11. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2023.
12. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA updates labeling for GLP-1 agonists. 2023.
13. European Medicines Agency. Wegovy Assessment Report. 2022.
14. Novo Nordisk. SELECT Trial Results Presentation. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. All other trademarks are property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.